Hematology - Hematopoietic stem cells take advantage of 'junk' RNA to replenish the blood system
Can't see this email? View it online
   
  Hematology  
  The latest hematology news from News Medical  
 

Top cell therapy targets for hematological malignancies Top cell therapy targets for hematological malignancies

Till April 2021, according to the data published on ClinicalTrials.gov, there are 1,358 active cell therapy trials, among which most trials are focusing on hematological malignancies. Typical targets include CD19, BCMA, and CD22.

ACROBiosystems offers a series of CAR-T target proteins for hematological tumor research, such as CD19, BCMA, CD20, and CD30 products, which are suitable for detecting CAR expression in clinical trials.

Find Out More
 
   Hematopoietic stem cells take advantage of 'junk' RNA to replenish the blood systemHematopoietic stem cells take advantage of 'junk' RNA to replenish the blood system
 
Chemotherapy is widely used to treat cancer patients. During the treatment, chemotherapeutic agents affect various biochemical processes to kill or reduce the growth of cancer cells, which divide uncontrollably in patients.
 
   Researchers develop new therapeutic approach for treating acute myeloid leukemiaResearchers develop new therapeutic approach for treating acute myeloid leukemia
 
Leukemia stem cells are rare cells that can renew themselves while continuing to generate malignant cells known as leukemic blasts. These cells are difficult to eradicate using chemotherapy drugs and frequently lead to recurrence of leukemia.
 
 A new guide for cancer-associated thrombosis
 
A new guide for cancer-associated thrombosisEver since the association between cancer and thrombosis was reported by Jean-Baptiste Bouillaud in the early 19th century, cancer-associated thrombosis has remained a challenging domain of cancer management.
 
 
 New risk score system to accurately predict leukemia relapse
 
New risk score system to accurately predict leukemia relapseLeukemia is a group of blood cancers that affects thousands of people worldwide. However, with advances in medicine, several different types of leukemia can be effectively treated with donor stem cells through allogenic stem cell transplantation (allo-SCT).
 
 
 UCLA professor honored for contributions to the field of hematology
 
UCLA professor honored for contributions to the field of hematologyDr. Elizabeta Nemeth, professor of medicine and director of the Center for Iron Disorders at the David Geffen School of Medicine at UCLA, has been awarded the 2021 William Dameshek Prize by the American Society of Hematology (ASH) for her contributions to the field of hematology.
 
 
 Protein markers in chronic lymphocytic leukemia may help determine patients' prognoses
 
Protein markers in chronic lymphocytic leukemia may help determine patients' prognosesChronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. New research published in the Journal of Leukocyte Biology reveals that certain protein markers may indicate which patients have stable forms of CLL and which have more aggressive types.